InstalabAFP & AFP-L3
Should you take a AFP & AFP-L3 test?
This test is most useful if any of these apply to you.
2 Biomarkers Included
- AFPMeasures the total amount of a liver protein that rises with cell damage, regeneration, or cancer. It sets the baseline the cancer-linked fraction is read against, but is too nonspecific to stand alone.A high level flags liver activity of some kind, but cannot by itself distinguish a tumor from benign injury or inflammation.
- AFP-L3Measures the sugar-coated fraction of that same protein, reported as a percentage. This form comes largely from cancerous liver cells, making it far more specific for cancer than the total.A rising percentage, even when total protein is low or normal, points toward cancer-type biology and warrants imaging.
About AFP & AFP-L3
Liver cancer remains one of the deadlier cancers in the United States, and fatty-liver and alcohol-related forms of it are still on the rise even as the overall rate has leveled off. It tends to grow quietly in people who already know their liver is under strain. This pair of blood tests looks for the earliest chemical fingerprints of that cancer, before a tumor is large enough to feel or easy to see on a scan.
One test measures a protein your liver makes. The other reads a sugar-coated version of that same protein that tends to come specifically from cancerous liver cells. Together they help answer a question a single number cannot: is a rising signal coming from an injured liver, or from a tumor?
What This Panel Reveals
The first test measures a protein called alpha-fetoprotein (AFP), which healthy adult livers make in small amounts. It climbs when liver cells are damaged, regenerating, or turning cancerous, so hepatitis and cirrhosis can push it up with no cancer present. On its own it is a blunt tool: AFP is elevated in only 60% to 80% of liver cancers, and it rises for plenty of harmless reasons.
The second test looks at the shape of that same protein. A fraction of AFP carries an extra sugar tag (a process called core fucosylation), and this sugar-coated form is labeled AFP-L3. It is reported as a percentage of your total AFP, and it is made largely by cancerous liver cells rather than merely injured ones. So the panel separates how much of the protein you have from what kind it is.
How to Read Your Results Together
The value here is in the combination. The percentage of the cancer-linked form (AFP-L3) matters most when read against your total protein level (AFP). The most common threshold for a positive AFP-L3 is 10%, with levels above 15% considered more specific for cancer.
| Pattern | What It Suggests |
|---|---|
| Normal AFP, low AFP-L3% | Reassuring. No current chemical signal of a tumor, though it does not fully rule cancer out. |
| High AFP, low AFP-L3% | More likely benign. Points toward liver injury, inflammation, or regeneration rather than cancer. |
| High AFP-L3%, even at low AFP | Concerning. The cancer-type protein signature can appear before total AFP rises much at all. |
| Both elevated | Strongest signal. Warrants prompt imaging and specialist review. |
Real studies show why the pairing helps. In one referral group, among people with a total AFP in the common gray zone of 10 to 200, an AFP-L3 above 10% caught about 71% of cancers while correctly clearing 63% of benign cases, and an AFP-L3 above 35% reached 100% specificity. In cirrhosis, AFP alone separated cancer from benign disease with about 71% specificity, compared with roughly 92% for AFP-L3.
What This May Mean for Your Risk
Emerging evidence suggests the cancer-linked fraction also carries forward-looking information. In people with chronic liver disease followed over years, an AFP-L3 of 3.5% or higher was associated with roughly a fivefold higher chance of later developing liver cancer. When total AFP stayed under 20, an AFP-L3 of 4.9% or higher was linked to an even stronger association. Standardized frameworks for using these numbers are still evolving, so they are best read as risk signals rather than verdicts.
Pooled analyses of people already diagnosed also link a higher pretreatment AFP-L3 to worse survival, reflecting more aggressive tumor biology. The practical point for surveillance is timing: both markers tend to start rising about 6 months before a tumor is diagnosed, and the cancer-linked form can climb before imaging catches anything.
What to Do with Your Results
These tests do not diagnose cancer by themselves. They sharpen the picture alongside imaging, and the cancer-linked fraction is cleared by the U.S. Food and Drug Administration (FDA) as an aid to assessing liver cancer risk, not as a replacement for an ultrasound. If your AFP-L3 comes back elevated, the next step is imaging and a hepatologist, a doctor who specializes in the liver.
A normal panel is not an all-clear, because the cancer-linked form misses many early tumors (its sensitivity for early disease is often only around a third). If you are actively watching your liver, retest every 6 months, the same interval used for liver cancer surveillance. The trend across draws tells you more than any single reading.
When Results Can Be Misleading
Both tests share a few blind spots worth knowing. The AFP-L3 percentage needs enough total AFP to measure reliably, so a very low total AFP can make the percentage unstable. A flare of hepatitis or advanced liver failure can move both numbers without cancer, and pregnancy raises AFP as a normal part of carrying a baby.